EUVIMEDEUVIMED entdecken
Crossref

In-Vitro Evaluation of the Anti-Inflammatory Potential of Empagliflozin Via Nf-Κb Pathway Inhibition

Pritiksha Raj, Priyanka Karandikar, Neha N. Kadam, Abhimanyu Kumar Jha, Ajaz Assad Lone, Supriya Supriya, Dushmanta Kumar Padhi, Joel Mart E

International Journal of Drug Delivery Technology · 02.06.2026 · 16 (43s)

DOI: 10.25258/ijddt.16.43s.79 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 02.06.2026. Verfasst von Pritiksha Raj und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, exhibits profound cardioprotective and renoprotective benefits that extend beyond its primary role in glycemic control. Emerging evidence suggests these pleiotropic effects are driven by intrinsic immune-modulating properties. This study aimed to systematically evaluate the in vitro anti-inflammatory efficacy and the underlying molecular mechanisms of empagliflozin in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.

Methods

Macrophages were pre-treated with safe, non-cytotoxic concentrations of empagliflozin (10, 25, and 50 μM), determined via CCK-8 assay, prior to stimulation with LPS (1 μg/mL). Extracellular nitric oxide (NO) production was quantified using the Griess reagent, and the secretion of primary pro-inflammatory cytokines (TNFα, IL-6, and IL-1β) was measured via highly sensitive enzyme-linked immunosorbent assays (ELISA). Compartmentalized protein extraction and Western blotting were executed to evaluate the modulation of the nuclear factor-kappa B (NF-κB) signaling axis.

Results

Empagliflozin maintained macrophage viability (>96%) at all tested doses. Upon LPS stimulation, empagliflozin dose-dependently and significantly (p < 0.001) attenuated the hyper-secretion of NO, TNF-α, IL-6, and IL-1β. Mechanistic evaluations revealed that empagliflozin robustly rescued cytosolic IκBα from degradation and simultaneously suppressed the phosphorylation of the p65 subunit (p-p65). Consequently, the subsequent nuclear translocation of p65 was dramatically abrogated.

Conclusion

Empagliflozin exerts potent, direct anti-inflammatory effects by systematically stabilizing IκBα and paralyzing the NF-κB signaling cascade. These findings provide critical mechanistic insights into its pleiotropic properties, further substantiating its therapeutic utility in mitigating chronic inflammation associated with severe cardio-metabolic disorders.

Zitieren

APA

Raj, P., Karandikar, P., Kadam, N. N., Jha, A. K., Lone, A. A., Supriya, S., Padhi, D. K., & E, J. M. (2026). In-Vitro Evaluation of the Anti-Inflammatory Potential of Empagliflozin Via Nf-Κb Pathway Inhibition. International Journal of Drug Delivery Technology, 16(43s). https://doi.org/10.25258/ijddt.16.43s.79

Vancouver

Raj P, Karandikar P, Kadam NN, Jha AK, Lone AA, Supriya S, et al. In-Vitro Evaluation of the Anti-Inflammatory Potential of Empagliflozin Via Nf-Κb Pathway Inhibition. International Journal of Drug Delivery Technology. 2026;16(43s). doi:10.25258/ijddt.16.43s.79

BibTeX
@article{Raj2026,
  author = {Raj, Pritiksha and Karandikar, Priyanka and Kadam, Neha N. and Jha, Abhimanyu Kumar and Lone, Ajaz Assad and Supriya, Supriya and Padhi, Dushmanta Kumar and E, Joel Mart},
  title = {In-Vitro Evaluation of the Anti-Inflammatory Potential of Empagliflozin Via Nf-Κb Pathway Inhibition},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {43s},
  doi = {10.25258/ijddt.16.43s.79}
}
Kostenlos starten →